All 41 TCGA ECs with a hotspot POLE mutation scored 3–5 points, while 13/41 (31.7%) ECs with a non‐hotspot POLE mutation scored ≥ 3 points, including 8/18 with exonuclease domain mutations, while 19/23 tumours with POLE mutations outside the exonuclease domain had scores ≤ 2, the exceptions being three tumours with score 3 (each of which had likely pathogenic mutations in POLD1: D316G, S478N, and L606M) and one scoring 5 points with a POLE R705W mutation. This evidence concerns the gene POLD1 and neoplasm.